Retatrutide entry (amino acid sequence, modifications, LY3437943 designation)
A phase 3 study (NCT04822181), which enrolled 1200 patients with biopsy-proven MASH and fibrosis, is currently ongoing to assess the benefit of OW subcutaneous semaglutide 2 mg in this setting 93
Simple checks before every injection can reduce avoidable errors and improve treatment safety
Before starting any GLP-1 medication, understanding qualification requirements and BMI guidelines for GLP-1 treatment helps you have an informed conversation with the prescribing physician
Fatigue can often be managed by ensuring adequate rest and maintaining gentle physical activity where possible
However, the underlying mechanism for GLP-1 accomplishing this is not known, as whether or not GLP-1R is localised to the islet alpha-cell surface is a matter of debate